home All News open_in_new Full Article

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was […]


today 29 h. ago attach_file Other

attach_file Economics
attach_file Events
attach_file Science
attach_file Events
attach_file Events
attach_file Economics
attach_file Transport
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Politics
attach_file Economics
attach_file Economics
attach_file Technology
attach_file Other
attach_file Other
attach_file Other


ID: 1982245503
Add Watch Country

arrow_drop_down